Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/28947
Title: | Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival | Authors: | Aarts, B. M. Klompenhouwer, E. G. Dresen, R. C. LAENEN, Annouschka Beets-Tan, R. G. H. Punie, K. Neven, P. Wildiers, H. Maleux, G. |
Issue Date: | 2019 | Publisher: | SPRINGER | Source: | BREAST CANCER RESEARCH AND TREATMENT, 176(3), p. 597-605 | Abstract: | PurposeThe aim of this study was to determine the safety and efficacy of Mitomycin C (MMC) infusion in a large cohort of advanced liver metastatic breast cancer patients (LMBC) and to determine factors influencing overall survival (OS).MethodsWe retrospectively analysed LMBC patients, treated with MMC infusion between 2000 and 2017. Hepatic response was measured with baseline CT scans and first available CT scan after MMC infusion by RECIST 1.1 criteria. Adverse events were registered by the CTCAE version 5.0. OS and hepatic progression free survival (hPFS) were evaluated using Kaplan-Meier estimates. After univariable analysis, a stepwise forward multivariable (MV) prediction analysis was developed to select independent pre-treatment factors associated with OS.ResultsWe included 176 patients with a total of 599 MMC infusions, mostly heavily pre-treated patients with a median time from diagnosis of MBC to MMC infusion of 36.9months. RECIST evaluation of liver lesions (n=132) showed a partial response rate of 15%, stable disease of 43% and progressive disease in 17%. Adverse events grade 3 and 4 were reported in 17.5%. Median PFS was 5.5months and median OS was 7.8months. Significant independent baseline predictors of worse OS included number of prior systemic chemotherapy lines, prior liver ablation, higher liver tumour burden and elevated levels of bilirubin and ALT.ConclusionMMC infusion is safe and effective in advanced LMBC patients. An increased number of prior therapies, a higher liver tumour burden and elevated levels of bilirubin and ALT were associated with a worse OS. | Notes: | [Aarts, B. M.; Klompenhouwer, E. G.; Beets-Tan, R. G. H.] Netherlands Canc Inst, Dept Radiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands. [Aarts, B. M.] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, POB 5800, NL-6202 AZ Maastricht, Netherlands. [Dresen, R. C.; Maleux, G.] Univ Hosp Leuven, Dept Radiol, Herestr 49, B-3000 Leuven, Belgium. [Laenen, A.] KU Leuven Univ Hasselt, Dept Biostat & Stat Bioinformat, Kapucijnenvoer 35, B-3000 Leuven, Belgium. [Punie, K.; Neven, P.; Wildiers, H.] Univ Hosp Leuven, Dept Gen Med Oncol, Herestr 49, B-3000 Leuven, Belgium. | Keywords: | Metastatic breast cancer; Liver metastases; Chemo resistant; Intra-arterial therapy; Mitomycin C infusion;Metastatic breast cancer; Liver metastases; Chemo resistant; Intra-arterial therapy; Mitomycin C infusion | Document URI: | http://hdl.handle.net/1942/28947 | ISSN: | 0167-6806 | e-ISSN: | 1573-7217 | DOI: | 10.1007/s10549-019-05254-4 | ISI #: | 000472498400011 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
aarts 1.pdf Restricted Access | Published version | 1 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
1
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
4
checked on Apr 30, 2024
Page view(s)
92
checked on Sep 7, 2022
Download(s)
78
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.